NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $3.93 -0.07 (-1.75%) Closing price 07/29/2025 04:00 PM EasternExtended Trading$4.07 +0.14 (+3.44%) As of 09:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aquestive Therapeutics Stock (NASDAQ:AQST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aquestive Therapeutics alerts:Sign Up Key Stats Today's Range$3.85▼$4.0750-Day Range$2.27▼$4.3752-Week Range$2.12▼$5.80Volume846,248 shsAverage Volume1.13 million shsMarket Capitalization$390.37 millionP/E RatioN/ADividend YieldN/APrice Target$10.14Consensus RatingBuy Company Overview Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Read More Aquestive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreAQST MarketRank™: Aquestive Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 760th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.46) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.28% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 6.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.28% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 6.83%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.93 News SentimentAquestive Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aquestive Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.85% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Stock News HeadlinesAquestive Therapeutics, Inc.: Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial OfficerJuly 23, 2025 | finanznachrichten.deAquestive Therapeutics Names Sherry Korczynski as Chief Commercial OfficerJuly 22, 2025 | globenewswire.comDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. The policy removes certification barriers and classifies lightweight drones as "expendable" - clearing the path for frontline deployment. Now, one U.S. drone company is already seeing the impact. They just confirmed a direct sale of its Commander XL drone system to the Department of Defense. And that's backed by earlier contracts with top U.S. defense contractors for its modular, swarm-capable FPV systems.July 30 at 2:00 AM | The Tomorrow Investor (Ad)Aquestive Therapeutics Provides International Expansion Update for Anaphylmâ„¢ (epinephrine) Sublingual FilmJuly 15, 2025 | globenewswire.comAquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 7, 2025 | globenewswire.comInstitutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gainJuly 6, 2025 | finance.yahoo.comAquestive Therapeutics, Inc. Common Stock (AQST) - NasdaqJuly 5, 2025 | nasdaq.comAquestive Therapeutics Inc News (AQST) - Investing.comJuly 5, 2025 | investing.comSee More Headlines AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $3.56 at the beginning of 2025. Since then, AQST stock has increased by 10.4% and is now trading at $3.93. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.07. The firm had revenue of $8.72 million for the quarter, compared to analysts' expectations of $12.23 million. Read the conference call transcript. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Top institutional investors of Aquestive Therapeutics include Janney Montgomery Scott LLC (1.06%), Penbrook Management LLC (0.04%), First National Bank & Trust Co. of Newtown (0.02%) and USAdvisors Wealth Management LLC (0.01%). Insiders that own company stock include Alexander Mark Schobel and Cassie Jung. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and GE Aerospace (GE). Company Calendar Last Earnings5/12/2025Today7/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AQST CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Price Target for Aquestive Therapeutics$10.14 High Price Target$17.00 Low Price Target$7.00 Potential Upside/Downside+158.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.14 million Net Margins-100.02% Pretax Margin-100.05% Return on EquityN/A Return on Assets-50.31% Debt Debt-to-Equity RatioN/A Current Ratio4.87 Quick Ratio4.48 Sales & Book Value Annual Sales$57.56 million Price / Sales6.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-5.95Miscellaneous Outstanding Shares99,330,000Free Float91,531,000Market Cap$390.37 million OptionableOptionable Beta1.97 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:AQST) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.